Viabuilt Ventures Inc. (VBVT)

[hondaboost]

Wow! MAVT, pump to dump with nothing! No cash, no asset, no revenue, just worthless shares dumping.

https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11870822

[trader_ron]

BOOM, nice job

[greendolphin11]

very impressive

no news, no filings, no info, just BOOOM

GD11

[greendolphin11]

.08 x .10 boom

Could technically go back to last years long term support at 20 cents

GD11

[makinezmoney]

FANNNNNNNTASTIC !!!!!!!


Another Marvelous DAY !


Stupid Crazy low floater........ run like the wind.


$MAVT

[davidsson10]

Today's P&D: http://www.theotc.today/

[michaeldouglas]

Nice POP MAVT

[makinezmoney]

500k bidding at $0.05 ..... WOW WOW WOW

There is something serious up for sure now.


Maybe a $MAAFF type run in the making

$MAVT

[makinezmoney]

Back over $1 possibly......... whatta recovery that would be

Would love to see it happen :)

$MAVT

[Uboat]

mavt ------damn!!!!!!!

[makinezmoney]

Looks like a great day for a SUPER-RUN

$MAVT

[Uboat]

I might even buy more of this. The more I dig. The more it seems like a potential ROCKET: (CLINICAL STUDIES?)

Madison Ventures Inc., incorporated on September 14, 2009, focuses on development of products and devices for the treatment of anal fissures. The Company is engaged in licensing semi-occlusive wound dressing for ambulatory treatment of acute and chronic anal fissure. The Company is also engaged in the production, use, import, offer for sale, sell, lease, distribute, or otherwise commercialize its technology for uses classified as medical devices, or those otherwise approved as an over-the-counter (OTC) remedy.
The device, which the Company intends to develop and market, is a medical foam wrapped with semi-occlusive wound dressing serving as a physical barrier to cover the anal fissure and maintain a moist physiological environment at the fissure lesion. The device is for one-time use and is provided in a kit with a set of 10 semi-occlusive wound dressings for 10-day treatment. The Company's activities in Israel are focused on advancement of clinical studies and production of product for use in clinical studies. The clinical studies are being carried out at the Wolfson Medical Centre in Israel and in the Hospital Sagrat Cor in Barcelona, Spain

[$hellKing]

LOL I thought about what I would do if I didnt do this. I thought detective but darn they have to interview so many people so scratch that talking to people all day. But yeah u are right Private eye would be better bc they are kinda like a investigative journalist but got a cooler job I think. They can do things in the shadows...


Also thought about being a cure researcher. Im so relentless I prob would of found a few cures already if I had gone into those fields.

[Uboat]

You dig deep. You missed your calling... Private eye.

[Uboat]

See what he says... You never kno.lol

[$hellKing]

ocure ltd not much info out there on it


https://www.bloomberg.com/profiles/companies/1309390D:ID-ocure-ltd

https://www.israelbizreg.com/ocure-ltd

https://relationshipscience.com/ocure-ltd-o42266564#

[$hellKing]

Subsidiary MADISON-IL LTD


Hahascala Blvd. 17/114
6789036 Tel Aviv-Yafo
Israel


http://www.infobel.com/en/israel/madison_il_ltd/tel_aviv_yafo/IL100598666/businessdetails.aspx

[$hellKing]

Too bad they didnt put an email in this doc. could email Gene


https://www.sec.gov/Archives/edgar/data/1575975/000000000016061130/filename1.pdf

[$hellKing]

Well maybe something else will come about. Jump in a hot field for stocks would send this to the Heavens. pretty large insider ownership for a .01 .02 stock. usually these will be .05 .10 at very least. unless someone has unlimited supply from the failed deal and is selling shares

[$hellKing]

So basically its a step above a shell. Looks like both parties didnt hold up to their bargain.


Madison Ventures Inc. (“Company”) was incorporated in the State of Nevada as a for-profit company on September 14, 2009 and established a fiscal year end of March 31. The Company initially was engaged in the acquisition, exploration and development of natural resource properties. On February 27, 2015, the Company terminated the acquisition of the mineral claim and entered into a letter of intent with Ocure Ltd. (“Ocure”), pursuant to which the Company agreed to exclusively license certain technology from Ocure related to the development of products and devices for the treatment of anal fissures and on August 5, 2015, entered into an exclusive license agreement to Ocure’s semi-occlusive wound dressing for ambulatory treatment of acute and chronic anal fissure (the “Ocure License”). On July 9, 2015, the Company established the wholly-owned subsidiary Madison-IL Ltd., incorporated under the laws of the country of Israel to address the Company’s requirement for an Israeli company to operate and hold the assets associated with Ocure License. However, the Company has not made all payments required under the Ocure License and is in breach of that agreement, although Ocure has not provided formal notice of termination. The Israeli management team has not achieved the projected development milestones and the Company has elected to terminate the Ocure License. The Company has no revenues and has limited operating history.

[$hellKing]

Got to search these insiders and see if they have any good history


Title of Class





Name and

Address of

Beneficial

Owner (2)





Amount and

Nature of

Beneficial Ownership








Percent of

Common

Stock (1)






























common stock





Best Peak Holdings Limited






2,500,000








8.80 %

common stock





Cariza Avier






2,500,000








8.80 %

common stock





Diossel Ching






2,500,000








8.80 %

common stock





Morpheus Financial Corporation






2,500,000








8.80 %

common stock





Nicasio Apawan Jr.






2,500,000








8.80 %

common stock





Regina Thai






2,500,000








8.80 %

common stock





Maribel Fernandez






2,500,000








8.80 %

common stock





Mary Ann Cabal






2,500,000








8.80 %

common stock





Gene Gregorio (3)





1,000,000








3.52


%

All directors and executive officers as a group (1 person)











1,000,000








3.52


%

__________

(1)


The percentages above are based on 28,400,000 shares of our common stock issued and outstanding as of July 6, 2016

(2)


c/o Madison Ventures Inc., Loma de Bernal 3, 1208 Tamarind Road, Dasmarinas Village, Makati City, Metro Manila, Philippines 1222.

(3)


Appointed President, Secretary, Treasurer and Director on April 2, 2014.

[$hellKing]

This is the last deal they did I believe.


On May 31, 2016, the Company entered into a one year contract with Barcelona Boosting Business SL ("BBB") to coordinate a clinical trial of the Licensed Technology in Barcelona, Spain in a study for up to 25 patients (the "Study"). BBB will be compensated 20,000 EURO at the start of the contract and 18,500 EURO after the submission of the Study. During the term of the contract BBB will protect the Company's proprietary information, patents, patent applications, copyrights and other intellectual property rights. All inventions from the Study shall be the exclusive property of the Company.

[$hellKing]

They abandoned the mining area of bus and entered med field but then went quiet

Overview



We were incorporated in the state of Nevada on September 14, 2009. From inception until early 2015, we were engaged in the mineral exploration business.



During early 2015, we decided to abandon our mineral exploration properties and on February 27, 2015, we entered into a letter of intent with Ocure, pursuant to which we agreed to exclusively license certain technology from Ocure related to the development of products and devices for the treatment of anal fissures under terms of a license agreement to be negotiated between us and Ocure.



On August 5, 2015, as amended February 25, 2016, our company and Madison-IL Ltd. entered into an exclusive license agreement with Ocure to license Ocure's semi-occlusive wound dressing for ambulatory treatment of acute and chronic anal fissure, pursuant to Ocure's patents and patent applications and to its production, use, import, offer for sale, sell, lease, distribute, or otherwise commercialize the Licensed Technology for uses classified as medical devices, or those otherwise approved ultimately as an OTC (over-the-counter) remedy.



With this licensing we are focusing our efforts on the development of products for the treatment of anal fissures. We abandoned our efforts in the mineral exploration industry.



Based on the licensed technology, we intend to develop and produce propriety devices that present a novel approach for treating anal fissures that is safe and simple to use by patients with minimal discomfort.




4. Investment in technology license


On August 5, 2015, as amended February 26, 2016, the company entered into an exclusive license agreement (the "License Agreement") with Ocure and Madison-IL Ltd., a wholly-owned subsidiary of the Company incorporated in Israel on July 9, 2015 (the "Subsidiary"). Pursuant to the License Agreement, Ocure granted to the Subsidiary an exclusive, sub-licensable, worldwide, license (the "License") to Ocure's semi-occlusive wound dressing for ambulatory treatment of acute and chronic anal fissure, pursuant to Ocure's patents and patent applications (the "Licensed Technology") and to its production, use, import, offer for sale, sell, lease, distribute, or otherwise commercialize the Licensed Technology for uses classified as medical devices, or those otherwise approved ultimately as an OTC (over-the-counter) remedy.




F-10
Table of Contents



Under the License Agreement, the Company is obligated as consideration for the Licensed Technology to provide the Subsidiary $250,000 for the commercialization of the Licensed Technology, payable according to the following schedule: $10,000 upon execution of the Letter of Intent, $90,000 at the later of May 11, 2015 or the final signing date of the License Agreement (the "Effective Date"), and $50,000 on or before March 4, 2016, and $100,000 on or before April 8,2016 (collectively, the "First $250,000 Tranche"). The License Agreement Effective Date is November 11, 2015; the date approval of the Chief Scientist of the Israeli Ministry of the Economy was received. Upon the 6-month anniversary of the Effective Date, if the Company has paid the First $250,000 Tranche, then Ocure will transfer certain assets, as defined, to the Subsidiary, and the Company will be obligated to provide the Subsidiary a second $250,000 tranche, payable as follows: $100,000 on or before August 12, 2016, $100,000 on or before September 23, 2016, and $50,000 on or before October 28, 2016. The License Agreement terminates, on a country-by-country basis, the later of: (a) the date of expiration of the last to expire of Ocure's rights in Ocure Patents in such country or such other grant of statutory exclusivity, or (b) the end of a period of fifteen (15) years from the date of making the first commercial sale, as defined, in such country; unless sooner terminated pursuant to the terms of the License Agreement. As of March 31, 2016, the Company has advanced $131,850 to the Subsidiary and paid Ocure $10,000 in furtherance of the commercialization of the Licensed Technology. On May 30 and June 8, 2016, an additional $10,000 and $80,000, respectively, was advanced to the Subsidiary in furtherance of the commercialization of the Licensed Technology.



As of March 31, 2016, the Company has expended and aggregate of $70,998 recorded as the investment in technology license.

[$hellKing]

They had some deals but then went quiet. Philippines and Israel


Sample Contracts

Madison Ventures Inc. – Service Agreement (July 18th, 2016)

This service agreement is made and entered this day of 2016_by and between Madison Ltd. whose address is Ha`etzel 9, Ramat-Gan, Israel (hereinafter: "the Company") and Barcelona Boosting Business SL (B 66271586), whose address is: Paseo Bonanova 105, 3o3a, 08017 Barcelona (hereinafter: "BBB" or "BBB").

Madison Ventures Inc. – Amendment to Exclusive License Agreement Dated August 5, 2015 (March 1st, 2016)

Madison Ventures Inc. – Exclusive License Agreement Between Madison Ventures Inc. And Madison-Il Ltd. And Ocure Ltd. Date: August 5, 2015 (August 12th, 2015)

THIS EXCLUSIVE LICENSE AGREEMENT ("Agreement"), is entered into on August 5, 2015 by Ocure Ltd., an Israeli corporation with a principal address at High-Tech Village, Givat Ram Campus, Hebrew University, P.O. Box 39158, Jerusalem 91391, Israel ("Ocure"), Madison Ventures Inc., a Nevada corporation with its principal address at 1208 Tamarind Road, Dasmarinas Village, Makati City, Metro Manila, Philippines 1222 ("Madison"), and Madison-IL Ltd., an Israeli corporation with Israeli incorporation number 515285633 ("Madison Israeli Subsidiary").

Madison Ventures Inc. – Letter of Intent (March 12th, 2015)

The Public Company shall provide $250,000 USD to the Company pursuant to the terms of a Global Exclusive Licensing Agreement between the parties. The proceeds of the transaction to be provided to the Company shall be submitted on behalf of the Public Company to Company counsel for direct release to the Company based on the dollar amounts, timing and disbursement schedule as defined herein under Item 4 (iii). The funding will be utilized by the Company as required for the proper day to day management and operation of the business based on timed and scheduled release dates derived from budgets and specific target milestones provided by the Company to the Public Company and mutually agreed upon by the parties as a general basis for such release, prior to Closing. The budgets and milestones shall be presented to the Public Company by the Company no later than March 2nd, 2015, and are to be derived from the following:

Madison Ventures Inc. – Revised and Restated Mineral Property Option Agreement (July 16th, 2013)

NOW THEREFORE THIS AGREEMENT WITNESSETH that in consideration of the mutual covenants, conditions and premises herein contained, the sum of EIGHT DOLLARS now paid by each of the Parties (as hereinafter defined) to the other and for other good and valuable consideration (the receipt and sufficiency whereof being hereby acknowledged), the Parties do hereby covenant and agree as follows:

Madison Ventures Inc. – Contract (May 22nd, 2013)

Madison Ventures Inc. – Bylaws (May 22nd, 2013)

[$hellKing]

Transfer Agent



Our transfer agent is Globex Transfer, LLC, whose address is 780 Deltona Blvd., Suite 202, Deltona, Florida 32725, and whose telephone number is [phone].



Holders



As of July 6, 2016, we had 28,400,000 shares of our common stock issued and outstanding held by approximately 14 holders of record.

[Uboat]

mAYBE A RUN?

[Uboat]

BOING

[$hellKing]

Anyone ever speak to management? Wonder if they got anything planned 2017 or if the deal went through last time? This would be top notch. Seen OTC reporting cos do high vol and drop considerably then all of a sudden they run later on.


License Agreement



On February 27, 2015, we entered into a letter of intent (the “Letter of Intent”) with Ocure Ltd. (“Ocure”), an Israeli corporation, pursuant to which the Company would be obligated to exclusively license certain technology from Ocure under terms of a license agreement to be negotiated between the Company and Ocure. The Letter of Intent terminated when the Company did not make the second required payment, however the Company continued to negotiate with Ocure. On August 5, 2015, as amended February 26, 2016, the company entered into an exclusive license agreement (the “License Agreement”) with Ocure and Madison-IL Ltd., a wholly-owned subsidiary of the Company incorporated in Israel on July 9, 2015 (the “Subsidiary”). Pursuant to the License Agreement, Ocure granted to the Subsidiary an exclusive, sub-licensable, worldwide, license (the “License”) to Ocure’s semi-occlusive wound dressing for ambulatory treatment of acute and chronic anal fissure, pursuant to Ocure’s patents and patent applications (the “Licensed Technology”) and to its production, use, import, offer for sale, sell, lease, distribute, or otherwise commercialize the Licensed Technology for uses classified as medical devices, or those otherwise approved ultimately as an OTC (over-the-counter) remedy.



Under the License Agreement, the Company is obligated as consideration for the Licensed Technology to provide the Subsidiary $250,000 for the commercialization of the Licensed Technology, payable according to the following schedule: $10,000 upon execution of the Letter of Intent (paid February 27, 2015 to Ocure), $90,000 at the later of May 11, 2015 or the final signing date of the License Agreement (the “Effective Date”), and $50,000 on or before March 4, 2016, and $100,000 on or before April 8, 2016 (collectively, the “First $250,000 Tranche”). The Effective Date will occur upon satisfaction of the Condition Precedent, as defined in the License Agreement, and approval of the Agreement by the Chief Scientist of the Israeli Ministry of the Economy. The License Agreement Effective Date is November 11, 2015; the date approval of the Chief Scientist of the Israeli Ministry of the Economy was received. Upon the 6-month anniversary of the Effective Date, if the Company has paid the First $250,000 Tranche, then Ocure will transfer certain assets, as defined, to the Subsidiary, and the Company will be obligated to provide the Subsidiary a second $250,000 tranche, payable as follows: $100,000 on or before August 12, 2016, $100,000 on or before September 23, 2016, and $50,000 on or before October 28, 2016. The License Agreement terminates, on a country-by-country basis, the later of: (a) the date of expiration of the last to expire of Ocure’s rights in Ocure Patents in such country or such other grant of statutory exclusivity, or (b) the end of a period of fifteen (15) years from the date of making the first commercial sale, as defined, in such country; unless sooner terminated pursuant to the terms of the License Agreement. As of December 31, 2016 and March 31, 2016, the Company has advanced $221,850 and $131,850, respectively, to the Subsidiary and paid Ocure $10,000 in furtherance of the commercialization of the Licensed Technology. As such, the Company is in breach of its obligations under the License Agreement, but has not yet received notice of termination from Ocure. The Israeli management team has not achieved the projected development milestones and the Company has elected to terminate the Ocure License.



Immediately after the Effective Date of the License Agreement and for the period ending March 31, 2016 (as amended), the shareholders of Ocure and certain individuals designated by Ocure will have opportunity to purchase up to an aggregate of 7,100,000 (1,775,000 presplit) shares of the Company’s Common Stock at the par value of $0.001 per share. In addition, the Company will establish an incentive stock option plan reserving up to 20% of the Company’s issued share capital, as of the closing. The right to purchase an aggregate of 7,100,000 (1,775,000 presplit) shares of the Company’s Common Stock expired unexercised, but by mutual agreement the purchase right will be extended under similar terms.



In consideration of the license for the Licensed Technology and with respect to any inventions, improvement, development or enhancement based upon, consists of, comprises, contains or incorporates the Licensed Technology invented following the Effective Date by the Subsidiary, its affiliate or sublicensee (the “New Inventions”), the Subsidiary will pay to Ocure royalties calculated as 5% of gross sales. In addition, the Subsidiary will pay to Ocure 20% of any cash or non-cash consideration received, whether for sublicense initiation fee, annual fee, sublicense milestone payments, or other such non-sale based royalty consideration payable by a sublicense as consideration for or under a sublicense. As the Company is in breach of the License Agreement, it is highly doubtful that the terms of the License Agreement will be carried out. The Israeli management team has not achieved the projected development milestones and the Company has elected to terminate the Ocure License.

[$hellKing]

I think so too. Prob .04 .05s at least.

[$hellKing]

Looking good today. great potential bounce play. Could go up easily.imo

[michaeldouglas]

MAVT has good share structure, Current Filings and last Quarterly said looking for New Business Venture so yes has good Bounce Potentially but question is always When.

[makinezmoney]

Good timing... its about to go here

$0.01 to $0.024


$MAVT

[$hellKing]

In for some. You normally dont see a 30 mil OS fairly new stock go this far down with a under 30 mil OS S/S. Wish I had gotten a little cheaper but maybe they can get some professional move going on day this year.

[makinezmoney]

$1.82 share ??

Woooooooooo

[makinezmoney]

$MAVT going back up to $0.23/share

Just watch :)

https://www.linkedin.com/in/kanikagoenka



https://twitter.com/kanikagoenka

https://angel.co/kanikagoenka

************************************************










$MAVT

[makinezmoney]

$MAVT.... Party time... Ready to ROLL

Vetted Startups.


https://angel.co/madison-ventures

[HopScotch2]

Anyone know what happened here?

[protagonist12]

They wanted to be able to sell more shares at elevated prices while retail was locked out from selling.

[gabeh]

I wonder why they bothered with the 4:1 split?

[protagonist12]

MAVTD CEO- gotta support the clan somehow, hey that's a lot of mouths to feed!

[willlbone]

Climb the mountain and throw the virgin in the volcano chart pattern.

[gabeh]

The scam comes crashing down.

[willlbone]

Don't watch MADTV.

[gabeh]

Boiler room operation.

[Renee]

MAVT 4 for one forward split:

http://otce.finra.org/DLSymbolNameChanges

[Sleepy2016]

4:1 Forward Split just posted on the Daily List.

[Addiecaps]

About to get drilled.

[monoatomicgold]

Pretty well strucutured climb.

[HopScotch2]

Yes, it certainly has. Wonder what is up here.

[nodummy]

This ticker has made a heck of a climb since I started this forum at $1.82/share on February 18th.